Nepicastat hydrochloride is under clinical development by Acorda Therapeutics and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nepicastat hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nepicastat hydrochloride overview

Nepicastat (SYN117, RS-25560197) is under development for the treatment autoimmune diseases, intestinal enteritis including Crohn's disease and ulcerative colitis. It is administered through oral route in the form of capsule. The drug candidate is a competitive and selective inhibitor of the enzyme dopamine beta-hydroxylase (DBH) and serotonin receptor (5-HT).

It was under development for the treatment of cocaine dependence,  post traumatic stress disorder (PTSD) and solid tumors.

Acorda Therapeutics overview

Acorda Therapeutics (Acorda), is a biopharmaceutical company that discovers, develops, and markets therapies for treating patients with neurological disorders. The company’s portfolio encompasses marketed products for the treatment of multiple sclerosis (MS) and for the intermittent treatment of people with Parkinson’s taking levodopa or carbidopa who experience off episodes. The company sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.

For a complete picture of Nepicastat hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.